PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary OpGen Reports Second Quarter 2018 Financial Results And Provides Business Update
Revenue increases 12% to $0.8 million , net loss narrows 21% to $3.3 million Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today reported financial and operating results for the three and six months ended June
View HTML
Toggle Summary OpGen Announces Date of Second Quarter 2018 Financial Results Conference Call
GAITHERSBERG, Md., July 25, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that the Company will report financial results for the three and six months ended June 30, 2018 after close of the U.S. financial markets on Thursday, August 2, 2018 .
View HTML
Toggle Summary OpGen Modifies Terms of Debt with Merck Global Health Innovation Fund
GAITHERSBERG, Md., June 14, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it has negotiated modifications related to its $1,000,000 Second Amended and Restated Senior Secured Promissory Note (the “Note”), dated June 28, 2017 , to extend the maturity of the note and to pay
View HTML
Toggle Summary OpGen Presents Data at ASM Microbe 2018 Demonstrating High Accuracy of Acuitas® for Predicting Antibiotic Resistance in Urine Specimens
90% accuracy data presented for rapid antibiotic resistance prediction using Acuitas AMR Gene Panel and Acuitas Lighthouse on urine clinical specimens Prospective clinical trial in Colombia demonstrates 57% improvement in survival and reductions in antibiotic usage when OpGen rapid diagnostic test
View HTML
Toggle Summary OpGen’s Acuitas® AMR Gene Panel u5.47 Data to be Presented at ASM Microbe 2018
Company Sponsors Symposium on Rapid Pathogen Detection and Prediction of Antimicrobial Resistance in Urinary Tract Infections GAITHERSBURG, Md. , June 05, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that data on its Acuitas ® AMR Gene Panel u5.47 (RUO) and Acuitas Lighthouse
View HTML
Toggle Summary OpGen Reports First Quarter 2018 Financial Results and Provides a Business Update
Revenue increases 10% to $0.8 million , net loss decreases 39% to $3.0 million Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md. , May 08, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today reported financial and operating results for the three months ended March 31,
View HTML
Toggle Summary OpGen Announces Date of First Quarter 2018 Financial Results Conference Call
GAITHERSBURG, Md. , May 01, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that the Company will report financial results for the three months ended March 31, 2018 after close of the U.S. financial markets on Tuesday, May 8, 2018 . OpGen’s management team will host a live
View HTML
Toggle Summary OpGen Highlights Acuitas® Analytical Validation Data for Rapidly Predicting Antibiotic Resistance Using Drug Resistance Gene Profiles at ECCMID
DNA Sequencing prediction results and evaluation of Acuitas Resistome Test for infection control presented GAITHERSBURG, Md. , April 24, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it has presented analytical validation results for the Acuitas ® AMR Gene Panel u5.47
View HTML
Toggle Summary OpGen Completes Rapid Testing Clinical Trial in Colombia and Expands International Operations
GAITHERSBURG, Md. , April 19, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) OpGen announced today that it successfully completed a prospective clinical trial evaluating the impact of using rapid diagnostic testing for identification and treatment of bacteremia and fungemia in hospital
View HTML
Toggle Summary OpGen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides a Business Update
Acuitas® AMR Gene Panel u5.47 introduced for Research Use Only Fourth quarter revenue consistent with previous year; net loss decreases 38% year over year Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md. , March 15, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc.
View HTML